drugset / Trial / NCT00168181
Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients
Phase 3
Completed
220 enrolled
Alberta Health services
CancerCare Manitoba · collabJewish General Hospital · collabNewfoundland Cancer Treatment & Research Foundation · collabNotre-dame Hospital · collabOttawa Hospital Research Institute · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
This is a study to see whether the drug Salagen or salivary gland transfer is better for the prevention of dryness of the mouth in patients with head and neck cancer receiving radiation treatment.
Timeline
- Start
- 2002-04
- Primary completion
- —
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pilocarpine | Unknown | — | Oral |